Mesothelioma in Dogs
Laurena A. Kavula, DVM;
Kenneth S. Latimer, DVM, PhD; Perry J. Bain, DVM, PhD
Class of 2003 (Kavula), Department of Pathology (Latimer, Bain), College of Veterinary
Medicine, The University of Georgia, Athens, GA 30602-7388

Introduction
Mesotheliomas are rare
neoplasms that originate from ectodermal cells that line the
body cavities.1 Healthy mesothelium is composed of a flattened monolayer
of mesothelial cells that line the pleural, pericardial, and peritoneal cavities.
These cells
also cover the tunica albuginea of the testes.2 Mesothelial cells
are characterized by the presence of microvilli and desmosomes. They also have
the potential
to phagocytose cells and particulate matter. When mesothelial cells are perturbed
following inflammation or irritation, they may increase in size (hypertrophy)
and number (hyperplasia). Following fluid accumulation within the body cavities,
mesothelial cells
may exfoliate and implant on serosal surfaces. Mesotheliomas are malignant neoplasms.
Their exfoliated cells also can seed the body cavities. Although multiple tumors
often are
present, distant metastases are rare.1 Non-neoplastic mesothelial
cells affected by inflammation, irritation, or malignancy may have a similar
cytologic
appearance to mesothelioma cells.
Thus,
cytologic distinction of neoplastic and reactive mesothelial cells can be challenging
to
impossible.2
Signalment
Mesotheliomas usually occur
in older dogs, with an average onset at 8 years of age. However, documented
cases of mesothelioma have been reported in patients from as young as
7 weeks to as old as 15 years.2-4 Extremely early age of onset (7
weeks old) suggests that congenital mesothelioma may occur infrequently in the
dog.1 Bouvier des Flandres, Irish Setters, and German Shepherd Dogs appear to be at
greater risk
for tumor development,2 and mesotheliomas are more common in male
than in
female dogs.
Etiology
In humans, mesotheliomas have been directly correlated with exposure to asbestos.2 A
history of exposure to asbestos crystals is present in > 70% of human
cases. Occupations with a greater risk for the development of mesotheliomas
from asbestos
exposure include welding, construction, asbestos mining, automotive machinery,
and shipbuilding. Family members of these types of workers are also at an
increased risk for
neoplasia due to exposure to asbestos fibers on the clothing of workers. Humans
with asbestos exposure usually have an increased number of asbestos fibers
in their lungs (Fig.
1). Asbestos exposure results in genetic damage giving rise to a population of
mesothelial cells that begin to secrete growth factors and experience uncontrolled
growth. The loss of
tumor suppressor gene products aids in the malignant transformation of mesothelial
cells. Immunosuppression also has been documented in people with mesothelioma
and may play an
important role in the development of this cancer.1
 |
| Fig.
1. Microscopic
appearance of asbestos fibers
(photo from Mesothelioma
Help Network) |
Asbestos exposure also is believed to contribute significantly to the development of
mesotheliomas in dogs. Dogs with mesotheliomas often belong to people who have a lifestyle
or occupation with higher asbestos exposure.1 Dogs with mesotheliomas, like
their human counterparts, have been proven to have higher levels of asbestos fibers in
their lungs.3
Asbestos fibers are divided
into two forms, designated chrysotile and amphibole. In humans, a greater
risk of mesothelioma is associated with amphibole asbestos.1 Ferruginous bodies are fibers that are covered with ferritin and amorphous protein.
Typical ferruginous bodies have cores of amphibole asbestos. These bodies are
found in human lungs and are evidence of asbestos exposure. In a study involving
urban dogs and the
incidence of mesotheliomas, dogs with mesotheliomas had an increased number and
type of ferruginous bodies when compared with control dogs. Atypical ferruginous
bodies also have
been found in dogs with mesotheliomas; they were rarely present in control dogs.
Thus,
dogs in urban settings may have a higher risk for the development of mesothelioma.3 Finally, evidence also suggests that exposure to certain chemicals may increase
the risk
of mesothelioma.2 An example is pentachlorophenol (used as a, herbicide,
algaecide, defoliant, wood preservative, germicide, fungicide, and molluscicide),
which
has been shown to cause mesothelioma in rats.5
Clinical Signs
The greatest incidence
of mesotheliomas occurs in the pleural cavity, followed by the peritoneal
and pericardial cavities.2 More than one body cavity may be involved
in the neoplastic process.1 Clinical signs of disease usually are
evident for up to one month prior to diagnosis. The major clinical sign of mesothelioma
in the dog is
dyspnea secondary to body cavity effusions or a large, space-occupying mass.1,2 Effusion is the result of fluid exudation from the surface of the tumor or from
blocked
lymphatic channels.1 Effusion often results in abdominal discomfort,
respiratory distress, cough, tachypnea, and exercise intolerance.
Physical Findings
Upon thoracic auscultation,
dogs with marked pleural effusion will have muffled heart sounds, decreased
lung sounds, and weak peripheral pulse. Pulmonary edema and/or enlarged
to globoid heart also may be present. If abdominal mesothelioma is present, effusion
will
be associated with abdominal distension and lethargy.2 Hepatomegaly
also may be apparent. Sclerosing mesothelioma is seen in male dogs, especially
German Shepherd Dogs.
This form of mesothelioma is associated with thick fibrous linings of the abdominal
or pleural peritoneum. Movement of the abdominal viscera often is restricted
secondary to
fibrosis, resulting in vomiting and urinary abnormalities.1
Diagnosis
A definitive diagnosis of mesothelioma can be challenging, especially in the early
stages of disease. If effusion is detected upon physical examination, a complete blood
cell count, biochemical profile, urinalysis, radiographs, and ultrasound can provide
critical staging criteria. Ultrasound is often useful to evaluate any visceral involvement
in the neoplastic process. However, mesotheliomas not visible with ultrasound or CT
because they often fail to penetrate the surface of the viscera and may not form discrete
masses. In such instances, mesotheliomas may appear only as a diffusely thickened surface.2
In diagnosing mesotheliomas, it must be demonstrated that the neoplasm has originated
in the coelomic cavity and has metastasized via transcoelomic implantation. Whenever the
majority of neoplastic tissue is located on the coelomic surface, mesothelioma must be
considered in the differential diagnosis.1
Cytology
Cytological evaluation of effusion fluid may be helpful for the diagnosis of cardiac
disease, bacterial infection, or other neoplasms such as lymphoma. However, cytological
evaluation may not be diagnostic for mesothelioma.1 Primary cytomorphologic
criteria of malignancy include cellular aggregates, pleomorphism (variable cellular
appearance), anisocytosis (variation in cell size), anisokaryosis (variation in nuclear
size), multinucleation, prominent to irregular nucleoli, increased nuclear to cytoplasmic
ratio, monomorphic cellular appearance, and increased mitotic figures.6 Hyperplastic
mesothelial cells also may exhibit anisocytosis, anisokaryosis, increased nuclear to
cytoplasmic ratio, binucleate and multinucleate, and scattered mitoses. Any situation that
results in fluid accumulation within the body cavities can induce mesothelial cell
hyperplasia and exfoliation with an abnormal cellular morphology (Fig. 2). Therefore, the
differentiation between mesothelial cell hyperplasia and mesothelioma may be difficult or
impossible (Fig. 3).1 Furthermore, carcinomatosis (seeding of the body cavities
by malignant carcinoma cells) of any type may difficult or impossible to distinguish from
mesothelial cell hyperplasia and mesothelioma (Fig. 4).
Cytologic examination of pericardial effusions is less often diagnostic compared to
routine abdominocentesis or thoracocentesis. In a recent study, fifty pericardial
effusions were analyzed to determine the medical disorder. Approximately 74% of neoplastic
effusions (n = 19) were diagnosed correctly, while 13% of nonneoplastic effusions (n = 31)
were falsely positive for neoplasia. Based on these results, it was concluded that
analysis of pericardial fluid for cytological characteristics did not distinguish
neoplastic and nonneoplastic conditions.7
 |
 |
 |
| Fig. 2. Mesothelial
cell hyperplasia and hemorrhage in an abdominocentesis specimen from
a dog following blunt trauma (Wright stain). |
Fig. 3. Pleomorphic
mesothelial cells, nondegenerative neutrophils, and erythrocytes are
present in thoracic fluid of a dog with mesothelioma (Wright stain). |
Fig. 4. Pleomorphic
epithelial cells in the thoracic fluid of a dog with carcinomatosis (Wright
stain). |
Biopsy and Immunohistochemistry
Due to the fact that cytology
of effusion fluid frequently does not confirm a diagnosis of mesothelioma,
a definitive diagnosis must be made via biopsy (Fig. 5). Furthermore,
immunohistochemical staining often is necessary to differentiate a mesothelioma
from other
neoplasms.2 With the advancement of thoracoscopy and laparoscopy guided
biopsies, samples of diagnostic value can be obtained with minimal invasiveness
to the patient. Histopathologically, mesotheliomas can be epithelial, mesenchymal
or mixed
morphologic types. The epithelial form is most common in animals and resembles
carcinoma
or adenocarcinoma on histopathology.1 Sclerosing mesothelioma is a
variation of
the mesenchymal form. This form is similar to sarcoma on histopathology.1 Based
on histopathology of the tumor cells, common differentials include mesothelioma,
metastatic squamous cell carcinoma, adenocarcinoma, and sarcomas.1,7
 |
 |
 |
| Fig.
5. Histologic section of a mesothelioma invloving the pleura.
A solid nodule (left) is present on the pleural surface. Pleomorphic
mesothelial cells (center) are present on the surface and extend into
the subjacent tissue as nodules are formed (right). |
Immunohistochemical staining
can be useful in differentiating mesotheliomas and
carcinomas.1,7,10 Mesotheliomas have been shown to express both vimentin
and
cytokeratin (high and low molecular weight) intermediate filaments. Pulmonary
adenocarcinomas should express cytokeratins but not vimentin. Therefore,
immunohistochemical staining may be useful to differentiate carcinomas from mesotheliomas.1,7
Immunohistochemical staining
for antibody 3B5 reactivity, vimentin, and cytokeratins may be useful in
the diagnosis of canine mesotheliomas.10 Experimentally, a
monoclonal antibody (designated 3B5) has been developed using canine mesothelioma
cells as the immunogen. This monoclonal antibody has been found to bind with
high sensitivity to a
cytoplasmic antigen that is expressed in canine mesothelial cells. This antibody
can be used to identify reactive mesothelial cells in proliferative lesions.
Although the
monoclonal antibody can distinguish mesothelial cells from carcinoma cells, it
cannot differentiate mesothelioma cells from normal or hyperplastic mesothelial
cells. The
antibody does not stain fibroblasts, fibrosacromas, or stroma; therefore, it
may be useful in differentiating sarcomatoid mesotheliomas from sarcomas
or reactive fibroplasia.
Ultrastructure
Ultrastructurally, mesotheliomas often have long microvilli with primary and secondary
branching that surrounds the entire cell circumference. Neoplastic cells are connected by
desmosomes with prominent intracellular spaces. Neoplastic mesothelial cells also have a
large volume of cytoplasm with several bundles of tonofilaments around the nucleus,
profiles of rough endoplasmic reticulum, scattered glycogen granules, and mitochondria.3,7
Treatment
| Note: Treatment of animals should only be performed by a licensed veterinarian.
Veterinarians should consult a veterinary oncologist, the current literature, and current
pharmacological formularies before initiating any treatment protocol. |
Both surgical and medical management have been employed in the treatment of canine
mesotheliomas. Surgical excision often is not feasible in dogs with mesotheliomas because
the neoplasms are multifocal, locally invasive, metastasize via implantation and
lymphatics, and may surround vital structures.1,2,11 Surgical excision may
benefit some patients but by the time of diagnosis there usually is significant local
involvement and metastasis of the disease via implantation.1,2
Marked effusion from the neoplasm or from lymphatic blockage can be managed by repeated
thoracocentesis or pericardiocentesis.11 Patients may tolerate these procedures
for several months with an improvement in dyspnea, cardiac tamponade, or abdominal
distention. However, it eventually may be necessary to perform thoracocentesis or
pericardiocentesis every few days.4 Pericardectomy may serve as palliative
treatment in selected patients with pericardial effusion. Pericardectomy may prolong the
survival time of some dogs approximately 4 to 9 months. Partial pericardectomy via
thoracic endoscope resulted in a median survival time of only 38 days in dogs with
malignant pericardial effusions.2
A proper chemotherapeutic regimen is best chosen in consultation with a veterinary
oncologist. In general, vincristine, cyclophosphamide, and prednisone treatment have not
resulted in remission of mesotheliomas. In contrast, chemotherapy with mitoxantrone and
doxorubicin have resulted in complete remission of mesothelioma in some dogs.
Intracavitary cisplatin is currently the treatment of choice for canine mesothelioma
and seems to provide to most clinical benefit. Effusion fluid accumulation is reduced
quickly if cisplatin is effective. If the dog fails to respond to one or two intracavitary
treatments of cisplatin, further treatment is not indicated. Intravenous doxirubicin can
be administered concurrently with cisplatin for optimal response.2 Due to the
fact that the penetration of intracavitary chemotherapy is shallow (only 2-3 mm), large
masses will not be significantly reduced. In these cases, surgical debulking of the
mesothelioma combined with chemotherapy may be necessary.1 If pericardectomy is
combined with chemotherapeutic agents, survival may be greatly extended (one dog treated
with pericardectomy, intrathoracic and intravenous cisplatin, and intravenous doxorubicin
was free of disease at 27 months post treatment).1
The median survival time for untreated animals with mesotheliomas in any location is
difficult to determine. This is because mesotheliomas are rare and affected animals often
are euthanized when the neoplasm is diagnosed.1 Canine mesotheliomas are
similar to human mesotheliomas in their clinical and morphologic appearance. Humans with
mesotheliomas usually die from secondary complications of mesothelioma rather than the
tumor per se. However, mesothelioma in humans and dogs usually is rapidly
progressive and has a grave prognosis.3
References
1. Withrow SJ, MacEwen
EG: Small Animal Clinical Oncology, 3rd ed.
Philadelphia, W.B. Saunders Co., 2001, pp.656-660.
2. Ogilvie GK, Moore
AS: Managing the Veterinary Cancer Patient, 1st ed.
Trenton, Veterinary Learning Systems Co., Inc, 1995, pp. 441-444.
3. Harbison ML, Godleski
JJ: Malignant mesothelioma in urban dogs. Vet Pathol 20:531-540, 1983.
4. Kim J-H, Choi Y-K,
Yoon H-Y, Kweon O-K, Kim D-Y: Juvenile malignant mesothelioma in a dog.
J Vet Med Sci 64:269-271, 2002.
5.Chhabra RS, Maronpot
RM, Bucher JR, Haseman JK, Toft JD, Hejtmancik MR: Toxicology and carcinogenesis
studies of pentachlorophenol in rats. Toxicol Sci 48:14-20, 1999.
6. Rakich PM, Latimer
KS: Cytology. In: Latimer KS, Mahaffey EA, Prasse KW (eds):
Duncan and Prasse's Veterinary Laboratory Medicine: Clinical Pathology, 4th ed.
Ames, Iowa State Press, 2003, pp 304-330.
7. McDonough SP, MacLachlan
NJ, Tobias AH: Canine pericardial mesothelioma. Vet Pathol 29:256-260,1992.
8. Sisson D, Thomas
WP, Ruehl WW, Zinkl JG: Diagnostic value of pericardial fluid analysis
in
the dog. J Am Vet Med Assoc 184:51-55, 1984.
9. DiPinto MN, Dunstan
RW, Lee C: Cystic, peritoneal mesothelioma in a dog. J Am Anim Hosp Assoc
31:385-389, 1995.
10. Liu KX, Bird, AE,
Lenz SD, McDonough SP, Wolfe LG: Antigen expression in normal and neoplastic
canine tissues defined by a monoclonal antibody generated against canine
mesothelioma cells. Vet Pathol 31:663-673, 1994.
11. Ikede Bo, Zubaidy
A, Gill CW: Pericardial mesothelioma with cardiac tamponade in a dog.
Vet Pathol 17:496-500,1980.
Acknowledgement
"Fire Talk" © by
Suzanne Adams, CT (ASCP) is used with permission of the artist. Her website
sare Welcome
to Fine Art Images! and The
Art of Cytology. |